Suppr超能文献

超重、肥胖与糖尿病:全球趋势及更美好的未来?

Overweight, Obesity and Diabetes: Global Trends and a Better Future?

作者信息

McPake Barbara

机构信息

Nossal Institute for Global Health, School of Population and Global Health, University of Melbourne, Melbourne, Victoria, Australia.

出版信息

Health Syst Reform. 2025 Dec 31;11(1):2518797. doi: 10.1080/23288604.2025.2518797. Epub 2025 Jun 23.

Abstract

The related overweight, obesity and diabetes epidemics are more than five decades old and have progressed inexorably. A billion people in the world are now obese, and nearly a billion are diabetic. The belief that diabetes is caused by overweight and obesity has led to public health advice focused on lifestyle change as the main preventive approach. This advice has shifted over time, and some parts of the public health community have started to switch from a lifestyle to an environmental perspective. There is a growing but not yet conclusive evidence base that rather than diabetes being caused by overweight and obesity, the three conditions have a common third cause, and difficulties in controlling weight and blood glucose emerge in tandem. New classes of medications, including semaglutides and tirzepatides, effectively address these processes. They are in the early stages of development but have accumulated a safety record over the last decade. They are largely currently available only to those who can afford their relatively high cost, but new generations of related medications are capable of becoming lower cost, and wider access to them could transform the overweight, obesity and diabetes pandemics. There is a marked absence of enthusiasm for their potential role in the public health community. This appears to reflect stigmatized attitudes to overweight and obesity, which contrast with attitudes to diabetes. A successful medical treatment may be the key to resolving that stigma and reversing the three pandemics.

摘要

相关的超重、肥胖和糖尿病流行已持续了五十多年,且一直在无情地发展。目前全球有10亿人肥胖,近10亿人患有糖尿病。认为糖尿病由超重和肥胖引起的观念导致公共卫生建议将重点放在生活方式改变上,作为主要的预防方法。随着时间推移,这种建议发生了变化,公共卫生界的一些人已开始从生活方式视角转向环境视角。越来越多但尚未确凿的证据表明,并非糖尿病由超重和肥胖所致,而是这三种情况有一个共同的第三原因,且控制体重和血糖的困难是同时出现的。包括司美格鲁肽和替尔泊肽在内的新型药物能有效应对这些过程。它们尚处于研发早期,但在过去十年里积累了安全记录。目前它们基本上仅提供给那些能负担其相对高昂费用的人,但新一代相关药物有望降低成本,更广泛地获取这些药物可能会改变超重、肥胖和糖尿病的流行状况。公共卫生界对它们潜在作用明显缺乏热情。这似乎反映了对超重和肥胖的污名化态度,这与对糖尿病的态度形成对比。一种成功的药物治疗可能是消除这种污名并扭转这三种流行状况的关键。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验